The dominant left ventricular assist device: lessons from an era
Related Experiment Video
Updated: Oct 20, 2025

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
Published on: August 16, 2021
Amit Alam1,2, Gregory P Milligan1, Timothy Gong1,2
1Division of Advanced Heart Failure, Baylor University Medical Center, 3410 Worth Street, Suite 250, Dallas, TX, 75246, USA.
Abstract:
The production and distribution of the HeartWare ventricular assist device has come to an abrupt end, but with this end comes the opportunity to reflect upon lessons learned from its lifespan. Running counter to the standard of evidence-based practice, the era of the HeartWare ventricular assist device was marred with fragmented data in relation to its primary counterpart, the HeartMate III. This created an incomplete understanding of devices, limited individualized patient care, and effectively positioned providers to make inferences regarding device superiority. We briefly review pertinent literature on this topic among the most commonly implanted durable devices from the era, detail the inherent limitations of this data, and argue the necessity of randomized clinical trials among novel devices towards the optimization of patient care.
Related Concept Videos
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy II: Dilated Cardiomyopathy
Heart Failure VI: Adjunct Therapies
Cardiopulmonary Resuscitation III: AED Use
Heart Failure V: Medical Management
Heart Failure I: Introduction

